KEY FEATURES
| Full Name | Fibroblast Growth Factor 5 |
|---|---|
| Synonym | HBGF5; Smag82; Heparin-binding growth factor 5 |
| Assay Type | Competitive |
| Reactivity | Human |
| Range | 12.35-1000pg/mL |
| Sensitivity | 4.99pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 50μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human FGF5 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Human FGF5. During the reaction, Human FGF5 in the sample or standard competes with a fixed amount of Human FGF5 on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Human FGF5. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Human FGF5 in tested samples can be calculated by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human FGF5 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 50.68 | 120.65 | 479.88 | 46.75 | 128.53 | 511.16 |
| Standard deviation | 2.9 | 6.54 | 22.27 | 3.17 | 6.54 | 18.4 |
| CV(%) | 5.72 | 5.42 | 4.64 | 6.78 | 5.09 | 3.6 |
RECOVERY
The recovery of Human FGF5 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 92-105 | 98 |
| EDTA plasma (n=8) | 92-105 | 98 |
| Cell culture media (n=8) | 91-103 | 98 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human FGF5 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with FGF5 ELISA Kits
| FGFR1 ELISA Kit | publications with FGF5 and FGFR1 |
| FGFR2 ELISA Kit | publications with FGF5 and FGFR2 |
| FGFR4 ELISA Kit | publications with FGF5 and FGFR4 |
| FGFR3 ELISA Kit | publications with FGF5 and FGFR3 |
Pathways associated with FGF5 ELISA Kit
| Downstream Signaling Of Activated FGFR Pathway | Downstream Signaling Of Activated FGFR Pathway |
| FGFR Ligand Binding And Activation Pathway | FGFR Ligand Binding And Activation Pathway |
| FGFR1 Ligand Binding And Activation Pathway | FGFR1 Ligand Binding And Activation Pathway |
| FGFR1c Ligand Binding And Activation Pathway | FGFR1c Ligand Binding And Activation Pathway |
| FGFR2 Ligand Binding And Activation Pathway | FGFR2 Ligand Binding And Activation Pathway |
| FGFR2c Ligand Binding And Activation Pathway | FGFR2c Ligand Binding And Activation Pathway |
| FGFR3 Ligand Binding And Activation Pathway | FGFR3 Ligand Binding And Activation Pathway |
| FGFR3c Ligand Binding And Activation Pathway | FGFR3c Ligand Binding And Activation Pathway |
| FRS2-mediated Cascade Pathway | FRS2-mediated Cascade Pathway |
| IRS-mediated Signalling Pathway | IRS-mediated Signalling Pathway |
Diseases associated with FGF5 ELISA Kit
| Skin Diseases | publications with FGF5 and Skin Diseases |
| Disease Models, Animal | publications with FGF5 and Disease Models, Animal |
| Hypertension | publications with FGF5 and Hypertension |
| Alopecia | publications with FGF5 and Alopecia |
| Carcinoma | publications with FGF5 and Carcinoma |
| Heart Diseases | publications with FGF5 and Heart Diseases |
| Kidney Diseases | publications with FGF5 and Kidney Diseases |
| Inflammation | publications with FGF5 and Inflammation |
| Cell Transformation, Neoplastic | publications with FGF5 and Cell Transformation, Neoplastic |
| Nervous System Diseases | publications with FGF5 and Nervous System Diseases |
Organs/Tissues associated with FGF5 ELISA Kit
| Blood | publications with FGF5 and Blood |
| Skin | publications with FGF5 and Skin |
| Embryonic Tissue | publications with FGF5 and Embryonic Tissue |
| Muscle | publications with FGF5 and Muscle |
| Brain | publications with FGF5 and Brain |
| Bone | publications with FGF5 and Bone |
| Kidney | publications with FGF5 and Kidney |
| Connective Tissue | publications with FGF5 and Connective Tissue |
| Liver | publications with FGF5 and Liver |
| Lung | publications with FGF5 and Lung |